Login
Companies $ACRS
$3.66 +$0.05 (1.52%) After hours
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

aclaristx.com

How Do They Make Money?

Aclaris earns revenue from licensing intellectual property and providing laboratory services to third parties. License fees may be upfront; development and regulatory milestones are paid when achieved, and commercial milestones and royalties as sales occur.

revenue
SegmentShareRevenue
Contract research
24%
FY2022: 15%
Licensing
Licensed

76%
FY2022: 84%

Who Are Their Customers?

Third parties license Aclaris intellectual property and use its laboratory research services; Aclaris also seeks partners to develop, obtain approval for, or commercialize drug candidates. Its customers and revenue are based in the United States.

Do Revenues Turn Into Profits?

No. It lost $64.9M in FY2025.

Operating income, FY2025
−976% of revenue
▲ +46% (Loss) vs FY2024 (−$141.9M, −758%)
Net income, FY2025
−830% of revenue
▲ +51% (Loss) vs FY2024 (−$132.1M, −705%)
Free cash flow, FY2025
−603% of revenue
▼ −134% (Loss) vs FY2024 (−$20.2M, −108%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −55%
vs $3.3M in Q3 FY2025
Net income
▼ −27% (Loss)
vs −$14.6M in Q3 FY2025
Licensing share of revenue vs 85.3% in Q3 FY2025

Growing. Revenue grew 16% in 4 years, from $6.8M in FY2021 to $7.8M in FY2025, about 4% a year.

Broader candidate types The pipeline has broadened from the older report's internally developed, KINect-based drug candidates to include biologic programs, including monoclonal and bispecific antibodies, alongside small-molecule candidates.

Revenue over time
Contract research Licensing Other
$50M$25M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support